Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer

This trial is testing a combination of a targeted antibody drug with chemotherapy in people with triple-negative metastatic breast cancer (TNBC) — a type of breast cancer that lacks the three main receptors (hormone and HER2), making it harder to treat with standard targeted drugs. **You may be eligible if...** - You are 18 years or older - You have advanced or metastatic triple-negative breast cancer confirmed by biopsy - Your disease has progressed after previous chemotherapy (including adjuvant therapy or treatment within 6 months of systemic therapy) - You are in reasonably good physical condition (ECOG 0–1) - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have untreated or active brain metastases - You have had certain prior treatments that overlap with this study's drugs - You are pregnant or breastfeeding - You have significant heart, liver, or kidney problems - You have active autoimmune disease requiring steroids Talk to your doctor to see if this trial is right for you.